Related references
Note: Only part of the references are listed.Sofosbuvir With Peginterferon-Ribavirin for 12 Weeks in Previously Treated Patients With Hepatitis C Genotype 2 or 3 and Cirrhosis
Eric Lawitz et al.
HEPATOLOGY (2015)
Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents
Jens M. Kittner et al.
DIGESTIVE AND LIVER DISEASE (2014)
Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease
Benjamin Maasoumy et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2014)
Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
Mark S. Sulkowski et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Global epidemiology and genotype distribution of the hepatitis C virus infection
Erin Gower et al.
JOURNAL OF HEPATOLOGY (2014)
Restoration of HCV-specific CD8+T cell function by interferon-free therapy
Bianca Martin et al.
JOURNAL OF HEPATOLOGY (2014)
Strategies to manage hepatitis C virus (HCV) disease burden
H. Wedemeyer et al.
JOURNAL OF VIRAL HEPATITIS (2014)
Retreatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin
Jordan J. Feld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kris V. Kowdley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Peter Ferenci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890
Christophe Hezode et al.
JOURNAL OF HEPATOLOGY (2013)
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Eric Lawitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting
Benjamin Maasoumy et al.
PLOS ONE (2013)
Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy
Cheng-Yuan Peng et al.
JOURNAL OF HEPATOLOGY (2012)
Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: A prospective study
Marie Angele Robic et al.
JOURNAL OF HEPATOLOGY (2011)
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
Markus Cornberg et al.
LIVER INTERNATIONAL (2011)
Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices
Farhad Kazemi et al.
JOURNAL OF HEPATOLOGY (2006)
Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C
M Ziol et al.
HEPATOLOGY (2005)